Key Points
-
Parkinson's disease is a neurodegenerative disease that results from a loss of nigrostriatal dopaminergic neurons. Clinical features include bradykinesia, rigidity and tremor. The accompanying loss of non-adrenergic, serotoninergic and cholinergic neurons leads to the progression of 'non-motor' features.
-
Although dopamine-replacement therapies have been highly successful in improving some of the motor features of the disease, their value is limited by the development of other motor complications. Therefore there is a need for novel therapeutics, both for Parkinson's disease, and also for the motor complications that arise from the use of existing drugs.
-
The multiplicity of dopamine receptors in the brain offers a range of potential targets, but exploitation of drugs acting on specific receptor sub-types has been disappointing. 5-hydroxytryptamine (5-HT) receptor modulators — in particular those acting at 5-HT1A, 5-HT1B, 5-HT2A and 5-HT2C receptors — could be useful, particularly with respect to levodopa-induced dyskinesia.
-
Since the vast majority of pathways in the basal ganglia utilize glutamate and γ-amino butyric acid, these systems are obvious drug candidates, but targeting these receptor systems is fraughtwith potential complications. Recognition of the enhanced opioid peptide transmission in Parkinson's disease patients with levodopa-induced motor complications has raised the possibility of controlling these by targeting opioid transmission in the basal ganglia.
-
Central adenosine A2A receptors are relatively selectively expressed in the striatum, which is innervated by the dopaminergic nigrostriatal neurons lost in Parkinson's disease. Therefore, its antagonism has emerged as a leading candidate strategy for the improved treatment of Parkinson's disease.
-
Although no drug has yet been shown to be neuroprotective in Parkinson's disease, several including dopamine agonists and monoamine oxidase type B inhibitors, have been tested in clinical trials.
Abstract
Dopamine deficiency, caused by the degeneration of nigrostriatal dopaminergic neurons, is the cause of the major clinical motor symptoms of Parkinson's disease. These symptoms can be treated successfully with a range of drugs that include levodopa, inhibitors of the enzymatic breakdown of levodopa and dopamine agonists delivered by oral, subcutaneous, transcutaneous, intravenous or intra-duodenal routes. However, Parkinson's disease involves degeneration of non-dopaminergic neurons and the treatment of the resulting predominantly non-motor features remains a challenge. This review describes the important recent advances that underlie the development of novel dopaminergic and non-dopaminergic drugs for Parkinson's disease, and also for the motor complications that arise from the use of existing therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197–211 (2003).
Rascol, O. et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 34, 1484–1491 2000).
Holloway, R. G. et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol. 61, 1044–1053 (2004).
Katzenschlager, R. et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov. Disord. 20, 151–157 (2005).
Poewe, W. & Luessi, F. Clinical studies with transdermal rotigotine in early Parkinson's disease. Neurology 65, S11–S14 (2005).
Newman-Tancredi, A. et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and α(1)/α(2)-adrenoceptor. J. Pharmacol. Exp. Ther. 303, 805–814 (2002).
Jenner, P. in Principles of Treatment in Parkinson's Disease (eds Schapira, A. H. V. & Olanow, C. W.) 33–359 (Elsevier, Philadelphia, 2005).
Fahn, S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J. Neurol. 252 (Suppl. 4), iv37–iv42 (2005).
Olanow, W., Schapira, A. H. & Rascol, O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci. 23, S117–S126 (2000).
Calon, F. et al. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci. 23, S92–S100 (2000).
Brooks, D. J. & Sagar, H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J. Neurol. Neurosurg. Psychiatry 74, 1071–1079 (2003).
Mercuri, N. B. & Bernardi, G. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? Trends Pharmacol. Sci. 26, 341–344 (2005).
Perry, E. K. et al. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J. Neural. Transm. Park. Dis. Dement. Sect. 2, 149–158 (1990).
Asahina, M. et al. Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET. Acta Neurol. Scand. 91, 437–443 (1995).
Quik, M. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 27, 561–568 (2004).
Rodriguez-Puertas, R., Pazos, A. & Pascual, J. Cholinergic markers in degenerative parkinsonism: autoradiographic demonstration of high-affinity choline uptake carrier hyperactivity. Brain Res. 636, 327–332 (1994).
Katzenschlager, R. et al. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. CD003735 (2003).
Leroi, I. et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int. J. Geriatr. Psychiatry 19, 1–8 (2004).
Aarsland, D. et al. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatry 72, 708–712 (2002).
Emre, M. et al. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351, 2509–2518 (2004).
Werber, E. A. & Rabey, J. M. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J. Neural Transm. 108, 1319–1325 (2001).
Fabbrini, G. et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol. Sci. 23, 41–43 (2002).
Le Novere, N., Zoli, M. & Changeux, J. P. Neuronal nicotinic receptor α6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur. J. Neurosci. 8, 2428–2439 (1996).
Costa, G., Abin-Carriquiry, J. A. & Dajas, F. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res. 888, 336–342 (2001).
Jeyarasasingam, G., Tompkins, L. & Quik, M. Stimulation of non-α7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience 109, 275–285 (2002).
Allam, M. F. et al. Smoking and Parkinson's disease: systematic review of prospective studies. Mov. Disord. 19, 614–621 (2004).
Lucas, G., Bonhomme, N., De Deurwaerdère, P., Le Moal, M. & Spampinato, U. 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology 131, 57–63 (1997).
De Deurwaerdère, P. & Spampinato, U. Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J. Neurochem. 73, 1033–42 (1999).
De Deurwaerdère, P., Navailles, S., Berg, K. A., Clarke, W. P. & Spampinato, U. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J. Neurosci. 24, 3235–3241 (2004).
Nicholson, S. L. & Brotchie, J. M. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease- opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur. J. Neurol. 9 (Suppl. 3), 1–6 (2002).
Frechilla, D. et al. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 39, 288–296 (2001).
Numan, S. et al. Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway. Brain Res. Mol. Brain Res. 29, 391–396 (1995).
Fox, S. H. & Brotchie, J. M. 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov. Disord. 15, 1064–1069 (2000).
Bibbiani, F., Oh, J. D. & Chase, T. N. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology. 57, 1829–1834 (2001).
Chassain, C. & Durif, F. M. Modulation of serotonin receptors in MPTP-lesioned monkeys. Mov. Disord. 19, 412 (2004).
Olanow, C. W. et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. 27, 58���62 (2004).
Bara-Jimenez, W. et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov. Disord. 20, 932–936 (2005).
Bonifati, V. et al. Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol. 17, 73–82 (1994).
Oh, J. D., Bibbiani, F. & Chase, T. N. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp. Neurol. 177, 557–564 (2002).
Fox, S. H., Moser, B. & Brotchie, J. M. Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 151, 35–49 (1998).
Fox, S. H. & Brotchie, J. M. 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat. Eur. J. Pharmacol. 398, 59–64 (2000).
Gomez-Mancilla, B. & Bedard, P. J. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol. 16, 418–427 (1993).
Ashby, C. R. Jr. & Wang, R. Y. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24, 349–394 (1996).
Bymaster, F. P. et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87–96 (1996).
Grondin, R. et al. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 52, 771–776 (1999).
Durif, F. et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62, 381–388 (2004).
Katzenschlager, R. et al. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study. J. Neurol. Neurosurg. Psychiatry 75, 295–297 (2004).
Iravani, M. M. et al. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J. Neurosci. 23, 9107–9115 (2003).
Chung, K. A., Carlson, N. E. & Nutt, J. G. Short-term paroxetine treatment does not alter the motor response to levodopa in PD. Neurology 64, 1797–1798 (2005).
Meco, G. et al. Mirtazapine in L-dopa-induced dyskinesias. Clin. Neuropharmacol. 26, 179–181 (2003).
Parsons, C. G., Danysz, W. & Quack, G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38, 735–767 (999).
Nash, J. E. et al. The NR2B-selective NMDA receptor antagonist CP-101, 606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 188, 471–479 (2004).
Hadj Tahar, A. et al. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol. Dis. 15, 171–176 (2004).
Counihan, T. J. et al. Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: mesencephalic dopaminergic neurons. J. Comp. Neurol. 390, 91–101 (1998).
Feng, B. et al. Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br. J. Pharmacol. 141, 508–516 (2004).
Picconi, B. et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nature Neurosci. 6, 501–506 (2003).
Marino, M. J. et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc. Natl Acad. Sci. USA 100, 13668–13673 (2003).
O'Neill, M. J. et al. Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease. Eur. J. Pharmacol. 486, 163–174 (2004).
More, J. C. et al. Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology 47, 46–64 (2004).
Calon, F. et al. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex. Brain Res. 680, 43–52 (1995).
Calon, F. et al. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov. Disord. 18, 241–253 (2003).
Xu, K., Bastia, E. & Schwarzschild, M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol. Ther. 105, 267–310 (2005).
Jenner, P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin. Investig. Drugs. 14, 729–738 (2005).
Fink, J S. et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res. Mol. Brain Res. 14, 186–195 (1992).
Grondin, R. et al. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52, 1673–1637 (1999).
Mori, A. & Shindou, T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology 61, S44–S48 (2003).
Bara-Jimenez, W. et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61, 293–296 (2003).
Hauser, R. A., Hubble, J. P. & Truong, D. D. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61, 297–303 (2003).
Ascherio, A. & Chen, H. Caffeinated clues from epidemiology of Parkinson's disease. Neurology 61, S51–S54 (2003).
Chen, J. F. et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21, RC143 (2001).
Fredduzzi, S. et al. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J. Neurosci. 22, 1054–1062 (2002).
Bibbiani, F. et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 184, 285–294 (2003).
Fuxe, K. et al. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology 61, S19–S23 (2003).
Kachroo, A. et al. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J. Neurosci. 25, 10414–10419 (2005).
Coccurello, R., Breysse, N. & Amalric, M. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 29, 1451–161 (2004).
Bezard, E., Brotchie, J. M. & Gross, C. E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nature Rev. Neurosci. 2, 577–588 (2001).
Calon, F. et al. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J. Neuropathol. Exp. Neurol. 61, 186–196 (2002).
Henry, B. et al. μ- and δ-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp. Neurol. 171, 139–146 (2001).
Samadi, P., Gregoire, L. & Bedard, P. J. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. Neuropharmacology 45, 954–963 (2003).
Fox, S. et al. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Mov. Disord. 19, 554–560 (2004).
Rascol, O. et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov. Disord. 9, 437–440 (1994).
Hollt, V. Opioid peptide processing and receptor selectivity. Annu. Rev. Pharmacol. Toxicol. 26, 59–77 (1986).
Sadee, W., Wang, D. & Bilsky, E. J. Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sci. 76, 1427–1437 (2005).
Simonds, W. F. The molecular basis of opioid receptor function. Endocr Rev. 9, 200–212 (1988).
Mansour, A. et al. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18, 22–29 (1995).
Schapira, A. H. Etiology of Parkinson's disease. Neurology 66, S10–S23 (2006).
Dawson, T. M. & Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 302, 819–822 (2003).
Shults, C. W. et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59, 1541–1550 (2002).
Hunot, S. & Flavell, R. A. Apoptosis. Death of a monopoly? Science 292, 865–866 (2001).
Chen, H. et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60, 1059–1064 (2003).
Schapira, A. H. Disease modification in Parkinson's disease. Lancet Neurol. 3, 362–368 (2004).
Iravani, M. M., Haddon, C. O., Cooper, J. M., Jenner, P. & Schapira, A. H. Pramipexole protects against MPTP toxicity in non-human primates. J. Neurochem. 96, 1315–1321 (2006).
Gu, M. et al. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem. 91, 1075–1081 (2004).
Whone, A. L. et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann. Neurol. 54, 93–101 (2003).
Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287, 1653–1661 (2002).
Schapira, A. H. & Olanow, C. W. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291, 358–364 (2004).
Mytilineou, C. & Cohen, G. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J. Neurochem. 45, 1951–1953 (1985).
Tatton, W. G. & Greenwood, C. E. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J. Neurosci. Res. 30, 666–672 (1991).
Chiueh, C. C., Huang, S. J. & Murphy, D. L. Enhanced hydroxyl radical generation by 2′-methyl analog of MPTP: suppression by clorgyline and deprenyl. Synapse 11, 346–348 (1992).
Wu RM, Chiueh CC, Pert A, Murphy DL. Apparent antioxidant effect of L-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur. J. Pharmacol. 243, 241–247 (1993).
Wu, R. M., Chen, R. C. & Chiueh, C. C. Effect of MAO-B inhibitors on MPP+ toxicity in vivo. Ann. NY Acad. Sci. 899, 255–261 (2000).
Tatton, W. G., Ju, W. Y., Holland, D. P., Tai, C. & Kwan, M. (–)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 63, 1572–1575 (1994).
Wadia, J. S. et al. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (–)-deprenyl. J. Neurosci. 18, 932–947 (1998).
Parkinson Disease Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328, 176–183 (1993).
Akao, Y. et al. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett. 326, 105–108 (2002).
Am, O. B., Amit, T. & Youdim, M. B. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. 355, 169–172 (2004).
Maruyama, W., Takahashi, T., Youdim, M. & Naoi, M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm. 109, 467–481 (2002).
Jenner, P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology 63 (Suppl. 2), S13–S22 (2004).
Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561–566 (2004).
Grondin, R. et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125, 2191–2201 (2002).
Kordower, J. H. et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767–773 (2000).
Kordower, J. H. et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46, 419–424 (1999).
Nutt, J. G. et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60, 69–73 (2003).
Gill, S. S. et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nature Med. 9, 589–595 (2003).
Lang, A. E. et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59, 459–466 (2006).
Barker, R. A. Continuing trials of GDNF in Parkinson's disease. Lancet Neurol. 5, 285–286 (2006).
Schapira, A. H. & Obeso, J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann. Neurol. 59, 559–562 (2006).
Chaudhuri, K. R., Healy, D. G. & Schapira, A. H. Non-motor symptoms of Parkinson's disease: diagnosis and management Lancet Neurol. 5, 235–245 (2006).
Lang, A. E. & Obeso, J. A. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol. 3, 309–316 (2004).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
This manuscript was prepared by the authors following a workshop sponsored by Boehringer-Ingelheim.
Related links
Glossary
- Bradykinesia
-
Abnormally slow voluntary movements.
- Lewy body
-
Abnormal aggregates of protein (predominately α-synuclein) that develop inside nerve cells and displace other cell components.
- Dyskinesia
-
Involuntary writhing movements affecting head, trunk and limbs.
- Depotentiation
-
The reversal of long-term potentiation back to baseline levels.
- Indirect motor pathway
-
Globus pallidus-mediated control of motor activity.
- Microglial reaction
-
Inflammatory-mediated reaction.
Rights and permissions
About this article
Cite this article
Schapira, A., Bezard, E., Brotchie, J. et al. Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 5, 845–854 (2006). https://doi.org/10.1038/nrd2087
Issue Date:
DOI: https://doi.org/10.1038/nrd2087
This article is cited by
-
Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research
Metabolic Brain Disease (2023)
-
A sporadic Parkinson’s disease model via silencing of the ubiquitin–proteasome/E3 ligase component, SKP1A
Journal of Neural Transmission (2023)
-
Neuromodulation in Parkinson’s disease targeting opioid and cannabinoid receptors, understanding the role of NLRP3 pathway: a novel therapeutic approach
Inflammopharmacology (2023)
-
Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands targeting G-protein-coupled receptors
Scientific Reports (2022)
-
Methanolic Extract of Boswellia serrata Gum Protects the Nigral Dopaminergic Neurons from Rotenone-Induced Neurotoxicity
Molecular Neurobiology (2022)